[HTML][HTML] Recent developments in immunotherapy of acute myeloid leukemia
The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer
treatment in the past decade, both in oncology and hematology. The transfer of the …
treatment in the past decade, both in oncology and hematology. The transfer of the …
Immunotherapy for acute myeloid leukemia
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients
with acute myeloid leukemia (AML) remains poor. About half of the patients are not …
with acute myeloid leukemia (AML) remains poor. About half of the patients are not …
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330
C Krupka, P Kufer, R Kischel… - Blood, The Journal …, 2014 - ashpublications.org
Antibody-based immunotherapy represents a promising strategy to target and eliminate
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …
[HTML][HTML] T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell …
FM Schnorfeil, FS Lichtenegger, K Emmerig… - Journal of hematology & …, 2015 - Springer
Background T cell function is crucial for the success of several novel immunotherapeutic
strategies for the treatment of acute myeloid leukemia (AML). However, changes in …
strategies for the treatment of acute myeloid leukemia (AML). However, changes in …
Bifunctional PD-1× αCD3× αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
M Herrmann, C Krupka, K Deiser… - Blood, The Journal …, 2018 - ashpublications.org
The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - Wiley Online Library
Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
[HTML][HTML] New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
M Subklewe, C Geiger, FS Lichtenegger… - Cancer Immunology …, 2014 - Springer
Dendritic cell (DC)-based immunotherapy is a promising strategy for the elimination of
minimal residual disease in patients with acute myeloid leukemia (AML). Particularly …
minimal residual disease in patients with acute myeloid leukemia (AML). Particularly …
[HTML][HTML] Immunotherapy as a turning point in the treatment of acute myeloid leukemia
A Aureli, B Marziani, T Sconocchia, MI Del Principe… - Cancers, 2021 - mdpi.com
Simple Summary Despite recent progress achieved in the management of acute myeloid
leukemia (AML), it remains a life-threatening disease with a poor prognosis, particularly in …
leukemia (AML), it remains a life-threatening disease with a poor prognosis, particularly in …
Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
G Zugmaier, M Klinger, M Schmidt, M Subklewe - Molecular immunology, 2015 - Elsevier
Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced
member of bispecific T-cell engager (BiTE®) molecules. The clinical development program …
member of bispecific T-cell engager (BiTE®) molecules. The clinical development program …
[HTML][HTML] Targeting CD157 in AML using a novel, Fc-engineered antibody construct
Antibody-based immunotherapy represents a promising strategy to eliminate
chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated …
chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated …